- Silence Therapeutics said it had added a new asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.

The siRNA, or short interfering RNA, product candidate, called SLN360, silenced apolipoprotein, a component of lipoprotein, the company said.

Elevated lipoprotein levels have been associated with increased risk of cardiovascular disease, independent of additional risk factors.

'We are excited to add SLN360 to our pipeline of wholly owned assets aimed at addressing areas of significant unmet need,' chief executive David Horn Solomon said.

'Our data suggest that SLN360 significantly reduces serum lipoprotein in non-human primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing.'

'We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk.'

At 8:01am: [LON:SLN] Silence Therapeutics PLC share price was +2.8p at 57.6p

Story provided by